Good to Globe

G2GBIO practices the spirit of "respect for life" for all humanity around the world.

Good to Globe

G2GBIO practices the spirit of "respect for life" for all humanity around the world.

Good to Globe

G2GBIO practices the spirit of "respect for life" for all humanity around the world.

SCROLL
G2GBIO stands for "Good to Globe Biotechnology".
Our vision lies in practicing
"Respect for Life"
by supplying good medicines to patients all over the world.
Respect for Life

by G2GBIO
TECHNOLOGY

InnoLAMP
Technology

G2GBIO has developed its own InnoLAMP(Innovative Long-Acting MicroParticle) technology to overcome the limitations of conventional emulsion-based manufacturing methods and has succeeded in producing distinctive and competitive microspheres by applying it.
VIEW MORE

InteLAMP
Technology

G2GBIO's InteLAMP provides the effect of drugs released from sustained-release microspheres with uniform distribution within the tumor tissue selectively killing cancer cells.

VIEW MORE
R&D

Our mindset of “Challenge”, “Cooperation” and “Creativity” allows us to become a dynamic.

We have the best experts in the field of innovative new drug injectable development and possess cost-competitive mass production technology and platform technology that can be applied to various disease treatments

VIEW MORE
GMP

G2GBIO follows
the international
standards listed below

We possess a research facility equipped with a sustained-release microsphere clinical GMP facility and 10~20kg pilot equipment.

VIEW MORE
NEWS
VIEW MORE

G2GBio, Raises KRW 21.8 Billion in Pre-IPO Funding, Accumulates KRW 58..

G2GBio, Raises KRW 21.8 Billion in Pre-IPO Funding, Accumulates KRW 58 Billion in Total Investments,..

2023.11.17

Development of a one-month extended-release subcutaneous donepezil inj..

Development of a one-month extended-release subcutaneous donepezil injection... "World's first...

2023.10.16

The Spectacular Rookie Venture Company The sustained-release post-oper..

 The Spectacular Rookie Venture CompanyThe sustained-release post-operative pain treatment has ..

2023.09.21

"G2GBio Announces Once-Monthly Semaglutide (GB-7001) Development ..

"G2GBio Announces Once-Monthly Semaglutide (GB-7001) Development Results at American Diabetes A..

2023.06.29

G2GBIO Signs Master Service Agreement with Global Pharmaceutical Compa..

“G2GBIO Signs Master Service Agreement with Global Pharmaceutical Company for Microsphere Sustaine..

2023.04.26

G2GBio: "Positive Signal for Development of Monthly Donepezil (GB..

G2GBio: "Positive Signal for Development of Monthly Donepezil (GB-5001) Formulation" ..

2023.04.17

G2GBIO, "Remarkable outcomes in non-clinical study for their Sema..

G2GBIO, "Remarkable outcomes in non-clinical study for their Semaglutide microspheres"(Mon..

2023.04.11

G2GBio signs a Collaboration Agreement with a global pharmaceutical co..

G2GBio signs a Collaboration Agreement with a global pharmaceutical company for long-acting diabetes..

2023.02.02

G2GBio has been selected as an "international collaborative techn..

G2GBio has been selected as an "international collaborative technology development operator&quo..

2022.10.07

Korea Pharma, G2GBIO, Humedix ink deal for donepezil injection-based A..

Korea Pharma said Wednesday that it signed a joint development contract with G2GBIO and Humedix to d..

2022.10.05